Finch Therapeutics Group, Inc. (FNCH)
- Previous Close
0.00 - Open
12.75 - Bid 12.40 x 40000
- Ask 12.95 x 40000
- Day's Range
12.75 - 12.75 - 52 Week Range
0.80 - 15.85 - Volume
900 - Avg. Volume
2,395 - Market Cap (intraday)
20.473M - Beta (5Y Monthly) 1.26
- PE Ratio (TTM)
-- - EPS (TTM)
-8.80 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
www.finchtherapeutics.comRecent News: FNCH
View MorePerformance Overview: FNCH
Trailing total returns as of 5/7/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FNCH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FNCH
View MoreValuation Measures
Market Cap
20.47M
Enterprise Value
33.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.44
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-21.89%
Return on Equity (ttm)
-67.28%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-14.17M
Diluted EPS (ttm)
-8.80
Balance Sheet and Cash Flow
Total Cash (mrq)
16.04M
Total Debt/Equity (mrq)
203.87%
Levered Free Cash Flow (ttm)
-15.96M